Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2019 01:15 ET | Source: Novartis International AG

Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma

Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipiprant was well tolerated with adverse events balanced across treatment...
December 13, 2019 07:03 ET | Source: Novartis International AG

Novartis receives positive CHMP opinion for Beovu® (brolucizumab) for the treatment of wet AMD

In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one1 In a pre-specified secondary endpoint, fewer patients had intra-retinal...
December 09, 2019 14:45 ET | Source: Novartis International AG

Novartis Kymriah® demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting

Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more heavily pretreated patients1-3 Fewer known CAR-T cell therapy adverse...
December 06, 2019 01:15 ET | Source: Novartis International AG

Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy

Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versus mometasone furoate1 QMF149 showed improvement in peak expiratory...
December 05, 2019 01:15 ET | Source: Novartis International AG

Novartis expects to sustain long-term growth with a robust pipeline of 25+ potential blockbusters highlighted at R&D Day

Uniquely positioned with global scale, focus on innovative medicines, diversification across therapeutic areas and exposure to cutting-edge platforms60 projects in Phase 2 pipeline with 10+ advancing...
December 05, 2019 01:00 ET | Source: Novartis International AG

Novartis tender offer for The Medicines Company commences

Basel, December 5, 2019 — Novartis AG (NYSE: NVS) (“Novartis”) today announced that its indirect wholly-owned subsidiary, Medusa Merger Corporation, a Delaware corporation (“Purchaser”), has commenced...
November 24, 2019 15:00 ET | Source: Novartis International AG

Novartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of death

Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL...
November 17, 2019 10:45 ET | Source: Novartis International AG

Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF

Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compared to valsartan1 Entresto, compared to valsartan, demonstrated reduced...
November 15, 2019 15:06 ET | Source: Novartis International AG

New Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease

Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications1 Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.63 vs...
November 15, 2019 06:27 ET | Source: Novartis International AG

Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS)

If approved, Mayzent® (siponimod) will be the first and only oral treatment specifically indicated for patients with active secondary progressive multiple sclerosis (SPMS) in Europe[1]) CHMP opinion...